Last reviewed · How we verify
ACT-128800
ACT-128800 is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor.
ACT-128800 is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor. Used for Pulmonary arterial hypertension.
At a glance
| Generic name | ACT-128800 |
|---|---|
| Sponsor | Actelion |
| Drug class | endothelin receptor antagonist |
| Target | ET-A and ET-B receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the binding of endothelin-1 to its receptors, ACT-128800 reduces vasoconstriction and lowers blood pressure, which can be beneficial in treating pulmonary arterial hypertension.
Approved indications
- Pulmonary arterial hypertension
Common side effects
- Edema
- Headache
Key clinical trials
- Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis (PHASE3)
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (PHASE4)
- A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS (PHASE2)
- Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis (PHASE3)
- A Study of Ponesimod in Healthy Adult Participants (PHASE1)
- A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |